Weiqing Wang1, Jinkui Yang2, Gangyi Yang3, Yan Gong4, Sanjay Patel5, Candice Zhang6, Toshiyasu Izumoto7, Guang Ning1. 1. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Beijing Tongren Hospital, Capital Medical University, Beijing, China. 3. The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. 4. Boehringer Ingelheim Pharma, Ingelheim, Germany. 5. Boehringer Ingelheim, Bracknell, UK. 6. Boehringer Ingelheim International Trading, Shanghai, China. 7. Nippon Boehringer Ingelheim, Tokyo, Japan.
Abstract
BACKGROUND: Despite the increasing prevalence of type 2 diabetes mellitus (T2DM) in Asia, clinical trials for glucose-lowering therapies are often dominated by Caucasian and/or Western populations. The present Phase III randomized placebo-controlled double-blind, 24-week study evaluated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin added to metformin in Asian T2DM patients. METHODS: In all, 306 patients (n = 265 Chinese; n = 24 Malaysian; n = 17 Filipino), aged 18-80 years with HbA1c between ≥7.0 and ≤10.0% and onmetformin therapy were randomized (2:1) to either linagliptin 5 mg daily or placebo added to metformin. Antidiabetes drugs other than metformin were washed out prior to randomization. The primary endpoint was change in meanHbA1c from baseline after 24 weeks. RESULTS: Baseline characteristics were well-matched between the groups (overall mean [±SD] HbA1c 8.0 ± 0.8%). Adjusted mean (±SE) HbA1c decreased in the linagliptin and placebo groups by -0.66 ± 0.05 and -0.14 ± 0.07%, respectively (placebo-corrected difference -0.52 ± 0.09%; 95% confidence interval [CI] -0.70, -0.34; P < 0.0001). In patients with baseline HbA1c ≥8.5%, the placebo-corrected decrease in HbA1c was -0.89 ± 0.17% (P < 0.0001). Adverse events occurred in similar proportions in the linagliptin and placebo patients (27.3% and 28.0%, respectively) and few were considered drug-related (2.4% and 0.0%, respectively). Hypoglycemia occurred in 1.0% of patients in both groups. Linagliptin therapy was weight neutral. CONCLUSIONS:Linagliptin 5 mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled bymetformin.
RCT Entities:
BACKGROUND: Despite the increasing prevalence of type 2 diabetes mellitus (T2DM) in Asia, clinical trials for glucose-lowering therapies are often dominated by Caucasian and/or Western populations. The present Phase III randomized placebo-controlled double-blind, 24-week study evaluated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin added to metformin in Asian T2DM patients. METHODS: In all, 306 patients (n = 265 Chinese; n = 24 Malaysian; n = 17 Filipino), aged 18-80 years with HbA1c between ≥7.0 and ≤10.0% and on metformin therapy were randomized (2:1) to either linagliptin 5 mg daily or placebo added to metformin. Antidiabetes drugs other than metformin were washed out prior to randomization. The primary endpoint was change in mean HbA1c from baseline after 24 weeks. RESULTS: Baseline characteristics were well-matched between the groups (overall mean [±SD] HbA1c 8.0 ± 0.8%). Adjusted mean (±SE) HbA1c decreased in the linagliptin and placebo groups by -0.66 ± 0.05 and -0.14 ± 0.07%, respectively (placebo-corrected difference -0.52 ± 0.09%; 95% confidence interval [CI] -0.70, -0.34; P < 0.0001). In patients with baseline HbA1c ≥8.5%, the placebo-corrected decrease in HbA1c was -0.89 ± 0.17% (P < 0.0001). Adverse events occurred in similar proportions in the linagliptin and placebo patients (27.3% and 28.0%, respectively) and few were considered drug-related (2.4% and 0.0%, respectively). Hypoglycemia occurred in 1.0% of patients in both groups. Linagliptin therapy was weight neutral. CONCLUSIONS:Linagliptin 5 mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin.
Authors: Sanaz Kamalinia; Robert G Josse; Patrick J Donio; Lindsay Leduc; Baiju R Shah; Sheldon W Tobe Journal: Endocrinol Diabetes Metab Date: 2019-11-13
Authors: Nobuya Inagaki; Wenying Yang; Hirotaka Watada; Linong Ji; Sven Schnaidt; Egon Pfarr; Tomoo Okamura; Odd Erik Johansen; Jyothis T George; Maximilian von Eynatten; Julio Rosenstock; Vlado Perkovic; Christoph Wanner; Mark E Cooper; John H Alexander; Issei Komuro; Masaomi Nangaku Journal: Diabetol Int Date: 2019-10-22
Authors: Ronald Cw Ma; Stefano Del Prato; Baptist Gallwitz; Vyankatesh K Shivane; Diane Lewis-D'Agostino; Zelie Bailes; Sanjay Patel; Jisoo Lee; Maximilian von Eynatten; Maximiliano Di Domenico; Stuart A Ross Journal: J Diabetes Investig Date: 2017-09-16 Impact factor: 4.232